reports
Genmab Announces Changes to its Executive Committee
Genmab Announces Changes to its Executive Committee Media ReleaseCOPENHAGEN, Denmark; July 1, 2025 Birgitte Stephensen, Executive Vice President and Chief Legal Officer to retire after 23 years with Genmab A/SGreg Mueller joins as new Executive Vice President, General Counsel and Chief Legal Officer, effective July 1 (Nasdaq: GMAB) announced today that Birgitte Stephensen, Executive Vice President and Chief Legal Officer, will retire from Genmab after a successful tenure that spanned 23 years with the company. Greg Mueller joins Genmab A/S as Executive Vice President, General Counsel and...
Completion of Share Buy-back Program
Completion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 23, 2025, to June 26, 2025: Tradi...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 16 to June 20, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulat...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; June 17, 2025 – (Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 27,396 shares at DKK 1,025.00,2,790 shares at DKK 1,050.00, 150 shares at DKK 1,147.50,1,557 shares at DKK 1,161.00, and224 shares at DKK 1,334.50. P...
Transactions with shares and linked securities in Genmab A/S made by m...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; June 17, 2025 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to p...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 9 to June 13, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulate...
Genmab Announces Epcoritamab Investigational Combination Therapy Demon...
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) led to an overall response rate (ORR) of 87 percent and a complete response (CR) rate of 65 percent in patients with relapsed or refractory (R/R) ...
Millicom (Tigo) Strengthens South American Leadership with USD 380 Mil...
Millicom (Tigo) Strengthens South American Leadership with USD 380 Million Acquisition of Telefónica Ecuador Millicom (Tigo) Strengthens South American Leadership with USD 380 Million Acquisition of Telefónica Ecuador Key Highlights: The acquisition reinforces Millicom’s strategic position and operating scale in Latin America, strengthening its platform for long-term regional growth.The acquisition also enhances Millicom’s geographic diversification, with the addition of Ecuador — a stable, dollarized economy with a supportive macroeconomic outlook — strengthening overall cash flow ...
Millicom (Tigo) Announces Partial Closing of Infrastructure Deal with ...
Millicom (Tigo) Announces Partial Closing of Infrastructure Deal with SBA and Intention to Declare a Special Dividend of $2.50 per Share Representing Around 45% of the Proceeds Millicom (Tigo) Announces Partial Closing of Infrastructure Deal with SBA and Intention to Declare a Special Dividend of $2.50 per Share Representing Around 45% of the Proceeds Luxembourg, June 13, 2025 – Millicom International Cellular S.A. (NASDAQ: TIGO) today announced the partial closing of its previously disclosed transaction with SBA Communications Corporation (NASDAQ: SBAC), through the sale of LATI Internati...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; June 12, 2025 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 2 to June 6, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated...
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demons...
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Media ReleaseCOPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S®) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 monthsContinued evaluation of single-agent Rina-S 100 mg/m2 in patients with advanced endom...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from May 26 to May 30, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated ...
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Ann...
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; May 27, 2025 (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the 46th Goldman Sachs Annual Global Healthcare Conference in Miami, Florida at 8:00 AM EDT (2:00 PM CEST) on June 9, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from May 19 to May 23, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated ...
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio ...
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Media ReleaseCOPENHAGEN, Denmark; May 22, 2025 First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S®) in patients with recurrent/advanced endometrial cancer Presentation of long-term follow-up data from analysis of Phase 1/2 EPCORE™ NHL-1 study of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (Nasdaq: GMAB) announced today that it will present new...
Millicom (Tigo) to Acquire Telefónica’s Operations in Uruguay for USD ...
Millicom (Tigo) to Acquire Telefónica’s Operations in Uruguay for USD 440 Million, Expanding Presence in South America Millicom (Tigo) to Acquire Telefónica’s Operations in Uruguay for USD 440 Million, Expanding Presence in South America Key Highlights: Acquisition strengthens Millicom’s presence and scale across South America.Expected to be EFCF accretive starting in 2026.Diversifies Millicom’s cash flow sources in a country with a favorable macroeconomic outlook and investment-grade credit rating.Significant synergies anticipated across network, operations, and commercial integration.Po...
Millicom (Tigo) cancels 3,096,305 treasury shares
Millicom (Tigo) cancels 3,096,305 treasury shares Millicom (Tigo) cancels 3,096,305 treasury shares Luxembourg, May 21, 2025 – The Board of Directors of Millicom International Cellular S.A. (“” or the “Company”) approved the cancellation of 3,096,305 shares that will not be used for compensation programs, pursuant to the authorization granted by the extraordinary general meeting of shareholders held today and the share repurchase plan approved by the annual general meeting of shareholders held on May 23, 2024. As a result, the Company’s issued share capital will be reduced to USD 253,500,...
Results of the Millicom (Tigo) AGM and EGM held today
Results of the Millicom (Tigo) AGM and EGM held today Results of the Millicom (Tigo) AGM and EGM held today Luxembourg, May 21, 2025 – Millicom International Cellular S.A. (“”) held its Annual General Meeting (“AGM”) and Extraordinary General Meeting (“EGM”) of shareholders today. All of the AGM and EGM resolutions proposed by the Board of Directors and its Nomination Committee were adopted by Millicom’s shareholders. Resolving in favor of all the Nomination Committee’s proposals, the AGM set the number of directors at eight and re-elected María Teresa Arnal, Bruce Churchill, Blanca Tr...
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global ...
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference Media ReleaseCOPENHAGEN, Denmark; May 21, 2025 (Nasdaq: GMAB) announced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies Global Health Care Conference in New York City, New York at 9:20 EDT (3:20 PM CEST) on June 5, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.